QuantumScape Corp

Item 5. Other Information.

Securities Trading Plans of Directors and Executive Officers

During our last fiscal quarter, the following officers, as defined in Rule 16a-1(f), adopted a “Rule 10b5-1 trading arrangement” as defined in Regulation S-K Item 408, as follows:

On June 10, 2026, Dr. Timothy Holme, our Chief Technology Officer, adopted a Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 3,381,234 shares of our Class A Common Stock. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is until June 16, 2027, or earlier if all transactions under the trading arrangement are completed.

On June 5, 2026, Kevin Hettrich, our Chief Financial Officer, adopted a Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 426,000 shares of our Class A Common Stock. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is until August 23, 2027, or earlier if all transactions under the trading arrangement are completed.

No other officers or directors, as defined in Rule 16a-1(f), adopted and/orterminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Regulation S-K Item 408, during the last fiscal quarter.

Executive Officer Temporary Modified Work Arrangement

We are providing the following disclosures in lieu of filing a Current Report on Form 8-K relating to Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers):

On July 22, 2026, we and Dr. Timothy Holme, our Chief Technology Officer, agreed to a temporary modified work arrangement for the period from August 2026 through May 2027, after which he will resume his full responsibilities. The arrangement will allow Dr. Holme to spend an extended period with his family while continuing to contribute to the Company. During this period, Dr. Holme will remain an employee of the Company and continue to serve as Chief Technology Officer in a modified capacity, overseeing our long-term research and development priorities, while certain of his day-to-day responsibilities will be reassigned to other long-tenured members of our senior technical team. We value Dr. Holme’s ongoing leadership and look forward to his return to full duties.

In connection with the arrangement, the Compensation Committee of our Board of Directors approved changes to Dr. Holme’s compensation for this period, including pausing his base salary and the vesting of his restricted stock units subject solely to service-based vesting conditions. His other outstanding equity awards will continue to vest during this period in accordance with their existing terms.